What do different levels of multiple myeloma indicate about disease progression?

Reviewed by Yoshinori Abe, MD

Internal Medicine

Multiple myeloma progression can be tracked by measuring specific proteins in the blood. One key marker is B-cell maturation antigen (BCMA), a protein found on myeloma cells. Elevated BCMA levels in the bloodstream often indicate that the disease is advancing, while lower levels may suggest the treatment is working. Doctors also monitor other proteins, such as M-protein and free light chains, to get a fuller picture of how the cancer is responding to therapy.

Because protein levels and symptoms can shift subtly over time, it's important to recognize early warning signs. If you're experiencing unexplained fatigue, bone pain, frequent infections, or other concerning symptoms, don't wait to get clarity. Take a free, instant, online symptom check to better understand what your body may be telling you and confidently plan your next steps.

Reviewed for medical accuracy: 07/14/2026

What brings you in today?

Can I treat this myself Do I need to see a doctor Where should I go for care I'm concerned about a symptom Concerned about a possible condition My symptoms are getting worse Seeking a second opinion

Not seeing your question? No worries.

Submit your own Question

Explanation

Multiple myeloma is a type of cancer that affects the blood. It can be tricky to know how the disease is doing just by looking at symptoms. Doctors use different tests to understand the disease better.

One important test measures a protein called B-cell maturation antigen (BCMA) in the blood. High BCMA levels can mean that the disease is more active or getting worse. When the BCMA levels are lower, it might mean the disease is not as active.

According to the research, BCMA levels can help predict how the disease will behave. For example:

Reference 1 shows that baseline BCMA levels can predict disease outcomes.
Reference 2 notes that elevated BCMA levels are linked to disease progression.
Reference 3 indicates that BCMA levels can also predict outcomes in conditions related to multiple myeloma.

By understanding BCMA levels, doctors can better decide on treatment plans and monitor how well the treatment is working. If you're experiencing unusual symptoms or want to understand what might be affecting your health, try Ubie's free AI-powered symptom checker to get personalized insights in minutes.

(References)

Bujarski S, Goldwater MS, Regidor BS, Jew S, Daniely D, Swift RA, et al. (2021). Baseline serum B-cell maturation antigen levels predict .... European journal of haematology, 33993536.
Guo P, Wang Y, He H, Chen D, Liu J, Qiang W, et al. (2024). Elevated serum levels of soluble B-cell maturation antigen .... Clinical and experimental immunology, 38743453.
Visram A, Soof C, Rajkumar SV, Kumar SK, Bujarski S, Spektor TM, et al. (2021). Serum BCMA levels predict outcomes in MGUS and .... Blood cancer journal, 34168119.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.